1. Home
  2. MDWD vs WHF Comparison

MDWD vs WHF Comparison

Compare MDWD & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • WHF
  • Stock Information
  • Founded
  • MDWD 2000
  • WHF 2011
  • Country
  • MDWD Israel
  • WHF United States
  • Employees
  • MDWD N/A
  • WHF N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • WHF Finance Companies
  • Sector
  • MDWD Health Care
  • WHF Finance
  • Exchange
  • MDWD Nasdaq
  • WHF Nasdaq
  • Market Cap
  • MDWD 208.2M
  • WHF 212.0M
  • IPO Year
  • MDWD 2014
  • WHF 2012
  • Fundamental
  • Price
  • MDWD $20.13
  • WHF $8.89
  • Analyst Decision
  • MDWD Strong Buy
  • WHF Sell
  • Analyst Count
  • MDWD 2
  • WHF 4
  • Target Price
  • MDWD $35.00
  • WHF $10.83
  • AVG Volume (30 Days)
  • MDWD 58.5K
  • WHF 90.0K
  • Earning Date
  • MDWD 08-13-2025
  • WHF 08-07-2025
  • Dividend Yield
  • MDWD N/A
  • WHF 20.08%
  • EPS Growth
  • MDWD N/A
  • WHF N/A
  • EPS
  • MDWD N/A
  • WHF 0.39
  • Revenue
  • MDWD $19,213,000.00
  • WHF $86,143,000.00
  • Revenue This Year
  • MDWD $20.64
  • WHF N/A
  • Revenue Next Year
  • MDWD $25.71
  • WHF N/A
  • P/E Ratio
  • MDWD N/A
  • WHF $22.59
  • Revenue Growth
  • MDWD N/A
  • WHF N/A
  • 52 Week Low
  • MDWD $14.14
  • WHF $8.44
  • 52 Week High
  • MDWD $22.51
  • WHF $12.42
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 53.36
  • WHF 46.99
  • Support Level
  • MDWD $19.73
  • WHF $8.83
  • Resistance Level
  • MDWD $20.97
  • WHF $8.95
  • Average True Range (ATR)
  • MDWD 0.71
  • WHF 0.16
  • MACD
  • MDWD 0.06
  • WHF 0.01
  • Stochastic Oscillator
  • MDWD 57.08
  • WHF 34.47

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

Share on Social Networks: